Peptide Reference
LL-37
Cathelicidin Antimicrobial Peptide LL-37
The only known human cathelicidin antimicrobial peptide. Part of the innate immune system with broad antimicrobial activity and wound-healing properties.
Status
research
Category
healing
Typical cost
$80-150/vial (5mg)
Mechanism
Disrupts bacterial membranes, exhibits antimicrobial activity against bacteria, fungi, and viruses. Promotes wound healing, angiogenesis, and modulates immune responses.
Potential benefits
- Antimicrobial activity
- Wound healing
- Immune modulation
- Broad-spectrum protection
- Biofilm disruption
Reported side effects
- Limited human data
- Potential autoimmune activation
- Injection site reactions
Common dosing references
subcutaneous
100-500mcg · Daily or 3x weekly
4-8 weeks
topical
10-50mcg/mL · 2x daily
Until healed
Research notes
LL-37 antimicrobial activity
2002
Broad-spectrum antimicrobial activity against pathogens
LL-37 wound healing
2008
Accelerated wound healing and angiogenesis
Regulatory and sourcing notes
Research chemical only. Natural human peptide. Not FDA-approved for therapeutic use.
Research peptide. Natural human peptide. Used for infections and wound healing.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.